Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

Cotte, Laurent;Braun, Joséphine;Lascoux-Combe, Caroline;Vincent, Corine;Valantin, Marc-Antoine;Sogni, Philippe;Lacombe, Karine;Neau, Didier;Aumaitre, Hugues;Batisse, Dominique;de Truchis, Pierre;Gervais, Anne;Michelet, Christian;Morlat, Philippe;Vittecoq, Daniel;Rosa, Isabelle;Bertucci, Inga;Chevaliez, Stéphane;Aboulker, Jean-Pierre;Molina, Jean-Michel;for the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group;
clinical infectious diseases 2014 Vol. 59 pp. 1768-1776
151
laurent2014clinicaltelaprevir

Abstract

Retreatment with telaprevir, pegylated interferon, and ribavirin resulted in an 80% sustained virological response rate in HIV/hepatitis C virus–coinfected pati

Keywords

Citation

ID: 273793
Ref Key: laurent2014clinicaltelaprevir
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
273793
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet